Does size matter? Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy
Wolfgang Bethge,
Sarah Flossdorf,
Franziska Hanke,
Christoph Schmid,
Mark Ringhoffer,
Stefan Klein,
Bernd Hertenstein,
Johannes Schetelig,
Matthias Stelljes,
Thomas Schroeder,
Igor Wolfgang Blau,
Francis Ayuk,
Matthias Eder,
Robert Zeiser,
Katharina Fleischhauer,
Nicolaus Kröger,
Peter Dreger
Affiliations
Wolfgang Bethge
University Hospital Tuebingen, Tuebingen, Germany; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy
Sarah Flossdorf
Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, Ulm
Franziska Hanke
German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, Ulm
Christoph Schmid
University Hospital Augsburg, Augsburg
Mark Ringhoffer
Hospital Karlsruhe, Karlsruhe
Stefan Klein
University Hospital Mannheim, Mannheim
Bernd Hertenstein
Central Hospital Bremen, Bremen
Johannes Schetelig
German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy; University Hospital Dresden, Dresden
Matthias Stelljes
German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy; University Hospital Muenster, Muenster
Thomas Schroeder
University Hospital Essen, Essen
Igor Wolfgang Blau
University Hospital Charité Berlin, Berlin
Francis Ayuk
German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy; University Medical Center Hamburg, Hamburg
Matthias Eder
University Hospital Hannover, Hannover
Robert Zeiser
University Hospital Freiburg, Freiburg
Katharina Fleischhauer
German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, Ulm, Germany; University Hospital Essen, Essen
Nicolaus Kröger
German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy, Ulm, Germany; University Medical Center Hamburg, Hamburg
Peter Dreger
German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy; University Hospital Heidelberg, Heidelberg
We investigated the effect of center-specific variables on overall survival (OS) after allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML). Eligible were adult patients reported to DRST registry receiving first alloHCT for AML from a related or matched (>= 9/10 HLA-match) unrelated donor 2015-2021. Primary endpoint was OS at 12 months from alloHCT. Univariable and multivariable analyses after best subset selection was performed. Of 5328 patients, 83% received alloHCT in a high-volume center (≥40 alloHCT/year); 90% in a university hospital; 90% in a center performing alloHCT for ≥10 years; and 73% in a Joint Accreditation Committee IHCT-Europe and EBMT (JACIE) accredited center. 52% of the patients were in CR1, and ELN risk was adverse in 37% and intermediate in 42%. On multivariable analysis, center-specific factors predicting adverse 12-month OS were program duration